Latest Regulatory Pathways News

Page 2 of 36
OncoSil Medical delivered sharper commercial growth and a string of regulatory milestones in FY26, but the oncology device company remains heavily loss-making and dependent on future sales or fresh capital. Revenue rose 44% to $1.68 million while operating cash outflow reached $10.47 million.
Victor Sage
Victor Sage
27 Oct 2026
EMVision Medical Devices has taken its pivotal emu™ trial beyond 230 participants while preparing to add acute ischaemic stroke detection to the FDA validation program. The ASX-listed medtech ended September with $18.1 million in cash and $3.7 million in remaining grant funding.
Victor Sage
Victor Sage
26 Oct 2026
Echo IQ’s FDA-cleared EchoSolv AS platform processed 9,697 full-result assessments in the September quarter, while the company ended the period with A$107.8 million in cash. The stronger balance sheet gives it room to pursue US enterprise deployments, but commercial conversion and the unresolved EchoSolv HF regulatory pathway remain the key tests.
Victor Sage
Victor Sage
26 Oct 2026
Patagonia Lithium’s application for a 1,000-tonne lithium carbonate demonstration plant has passed the gazettal stage in Argentina, but final environmental approval remains outstanding. The company has also pushed back its Mineral Resource Estimate update by five weeks while it resolves conflicting porosity data.
Maxwell Dee
Maxwell Dee
23 Oct 2026
Australian Oil has moved its Surat Basin restart strategy closer to production, with Emu Apple-1 producing about 14 barrels of oil a day without water and Major-4 preparations advancing. The company ended the quarter with A$1.415 million in cash after raising A$1.404 million, but reported funding of about 2.7 quarters at its current outgoings.
Victor Sage
Victor Sage
22 Oct 2026
Cleo Diagnostics’ prototype ovarian cancer screening test met or exceeded every predefined performance target in a 247-person proof-of-concept study, including among 62 Stage I cases. The result moves the program into larger bridging and expanded studies, but it remains retrospective evidence rather than a validated screening test.
Ada Torres
Ada Torres
21 Oct 2026
CurveBeam AI has secured its strongest first-quarter HiRise sales result, gained China regulatory clearance and raised A$7.35 million to fund the next stage of commercialisation. The progress comes alongside lower customer receipts and a reported 4.3 quarters of cash runway.
Victor Sage
Victor Sage
21 Oct 2026
Actinogen Medical says its pivotal XanaMIA Alzheimer’s trial remains on course for topline results in November after the final patient visit was completed. The company also reported $15.9 million in cash, a further $5.3 million from option funding and a projected runway into late 2027 or 2028, assuming future trials are substantially partner-funded.
Ada Torres
Ada Torres
19 Oct 2026
Cleo Diagnostics has moved its pre-surgical ovarian cancer test into formal Analytical Validation, a key regulatory step before its planned FDA 510(k) submission in the first half of 2027. The three-batch program is expected to take about three months, but no validation results have yet been reported.
Victor Sage
Victor Sage
13 Oct 2026
Echo IQ has secured an FDA supervisory review of the regulator’s Not Substantially Equivalent decision for EchoSolv HF. The review creates a formal route for reconsideration, but does not change the current regulatory determination or guarantee clearance.
Victor Sage
Victor Sage
12 Oct 2026
Cavalier Resources has secured all primary approvals needed to advance Stage 1 mining at its Crawford Gold Project near Leonora. The regulatory milestone shifts attention to funding, site preparation and the finalisation of mining arrangements with SSH Mining.
Maxwell Dee
Maxwell Dee
8 Oct 2026
Brazilian Critical Minerals has reported striking economics for its Ema rare earths project, including a US$1.47 billion post-tax NPV, 105% IRR and six-month payback. The company’s A$7.87 million FY2026 loss, December debt maturity, permitting requirements and unresolved Drake dispute leave the development case dependent on execution and further funding.
Maxwell Dee
Maxwell Dee
28 Sept 2026

Browse the archive

Full archive